Governor Bill Ritter today applauded $23 million in grants and tax credits from the Affordable Care Act that will support important research by Colorado’s bioscience industry.
The awards will go to more than 60 Colorado companies.
“The Affordable Care Act is helping Colorado companies create jobs and bolster the economy while addressing our critical health care needs,” said Gov. Ritter. “Colorado companies are significantly benefiting from the new law, ranking in the top ten of all states receiving grants through this research program.”
The grants and tax credits will pay for 102 projects in the Qualifying Therapeutic Discovery Project (QTDP) program, awarded this week by the Internal Revenue Service (IRS), in conjunction with the U.S. Department of Health and Human Services.
“This is a unique program in which $1 billion was allocated for tax credits and grants for start-up companies in the bioscience industry to help encourage innovation, advance technology and help ensure that the U.S. remains competitive in this industry,” said Holli Baumunk, President & CEO of the Colorado BioScience Association. “Colorado has a nationally ranked bioscience cluster with the majority of companies being in the start-up phase. Demonstrating the tremendous entrepreneurial climate in the state, more than 100 projects within Colorado have been funded through this program, bringing in more than $23 million for research activities.”
The Colorado companies receiving awards include:
Accelr8 Technology Corporation
Actium Biosystems, LLC
Aktiv-Dry, LLC
Allos Therapeutics, Inc. – received funding for six projects
ApopLogic, Inc. – received funding for two projects
Aqueous Biomedical, Inc
ARCA Biopharma, Inc. – received funding for two projects
ArcScan, Inc.
AspenBio Pharma, Inc.
Beacon Biotechnology, LLC
BioAMPS International, Inc.
Biodesix, Inc. – received funding for six projects
BiOptix Diagnostics, Inc.
Bolder Biotechnology, Inc. – received funding for five projects
Cell Point
CeMines, Inc.
Cerapedics, Inc. – received funding for three projects
CereScan Corp.
Chata Biosystems, Inc.
Clovis Oncology, Inc.
Corgenix Medical Corp.
Crestone Inc. – received funding for two projects
EndoShape, Inc. – received funding for two projects
Eveia Medical, Inc.
Fertility Laboratories of Colorado, Inc.
Generations Medical Partners, LLC
GlobeImmune, Inc. – received funding for three projects
Greffex, Inc.
Hiberna Corporation
ICVRX, LLC
Inviragen, Inc. – received funding for two projects
Isogenis, Inc.
Kestrel Labs, Inc.
Lanx, Inc.
MBC Pharma, Inc.
Micro-Imaging Solutions, LLC
MicroPhage, Inc. – received funding for two projects
Miragen Therapeutics, Inc.
Myocept, Inc.
N30 Pharmaceuticals, LLC
Ocutronics, LLC
Otologics, LLC
Parascript, LLC
PARE Surgical, Inc.
Pathogen Systems, Inc.
PharmaJet, Inc.
Precision Photonics Corp.
ProFoldRx, Inc. dba BaroFold, Inc.
Protectstyle Corp.
Pyxant Labs, Inc. – received funding for two projects
Rocky Mountain Biosystems, Inc. – received funding for two projects
SomaLogic, Inc. – received funding for eight projects
Sophono Inc.
Source Precision Medicine Inc. dba Source MDx – received funding for two projects
St Cardio Technologies
St. Renatus, LLC
Sundance Diagnostics, Inc.
Surefire Medical, Inc.
ValveXchange, Inc.
Ventria Bioscience – received funding for three projects
Vitrolife, Inc.
Topics: 2010, Affordable Care Act, bioscience, business, clean energy, clean technology, Colorado, Department of Health and Human Services, economic development, economic growth, economic recovery, Economy, energy, govenrment, Governance, Governor Bill Ritter, health care, HHS, Internal Revenue Service, investment, IRS, Israel, memorandum of understanding, moniter, monitor, MOU, news, QTDP, Qualifying Therapeutic Discovery Project program, renewable energy, society, tax credits, U.S., United States, water
Print This Article in Plain Text
|
|